Limited Coverage Drugs - ezetimibe
Generic Name |
ezetimibe |
Strength |
10 mg |
Form |
tablet |
Special Authority Criteria |
Approval Period |
For the treatment of hypercholesterolemia in patients with established cardiovascular disease who are at high risk for future events:
|
Indefinite |
Practitioner Exemptions
-
None
Special Notes
- Target LDL-C levels are:
- For primary prevention, a ≥50% reduction in LDL-C from untreated baseline.
- For secondary prevention, an LDL-C ˂ 2.0 mmol/L.
- Ezetimibe is a regular benefit for Plan W (First Nations Health Benefits) recipients.